Briefing From The Editor -- GRFS Stock

By Harris Dyer • Wednesday, December 20 14:10 • Permanent Link

Mid-cap Health Care company Grifols has moved 0.9% so far today on a volume of 453,801, compared to its average of 723,301. In contrast, the S&P 500 index moved -0.0%.

Grifols trades -35.26% away from its average analyst target price of $16.32 per share. The 2 analysts following the stock have set target prices ranging from $15.07 to $17.58, and on average have given Grifols a rating of buy.

Anyone interested in buying GRFS should be aware of the facts below:

Grifols has moved 31.5% over the last year, and the S&P 500 logged a change of 22.9%
Based on its trailing earnings per share of 0.04, Grifols has a trailing 12 month Price to Earnings (P/E) ratio of 264.1 while the S&P 500 average is 15.97
GRFS has a forward P/E ratio of 9.9 based on its forward 12 month price to earnings (EPS) of $1.07 per share
The company has a price to earnings growth (PEG) ratio of 0.46 — a number near or below 1 signifying that Grifols is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 1.17 compared to its sector average of 4.08
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada and internationally.
Based in Barcelona, the company has 24,000 full time employees and a market cap of $9.43 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.